SEC Filing - IRIDEX

View:

irix-8k_20181101.DOCX.htm


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8‑K CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	November 1, 2018
(Date of Report (date of earliest event reported)

IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)

Delaware			0-27598	77-0210467
(State or other jurisdiction of incorporation or organization)			(Commission File Number)	(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)
		(650) 940-4700
		(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On November 1, 2018, IRIDEX Corporation issued a press release discussing revenues for its third fiscal quarter of 2018, which ended September 29, 2018. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



Item 9.01.	Financial Statements and Exhibits.



(d)	Exhibits




Exhibit No.		Description

99.1		Press Release dated November 1, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




		IRIDEX CORPORATION

By:		/s/ William M. Moore
		William M. Moore President and Chief Executive Officer

Date: November 1, 2018

-2-

irix-ex991_30.htm

Exhibit 99.1

IRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance

MOUNTAIN VIEW, Calif., November 1, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018.

Third Quarter Highlights

•

Cyclo G6™ product revenue increased approximately 23% year-over-year

•

Shipped 10,400 G6 probes

•

Shipped 117 G6 laser systems

•

Total revenue of $11.3 million

•

Received FDA Clearance to introduce updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market

•

Completed public offering of common stock with gross proceeds of $11.5 million

“Our solid performance in the third quarter includes year-over-year growth in shipments of G6 systems and probes,” said William M. Moore, President and CEO. “We are pleased with the expanding awareness and acceptance of MicroPulse technology driven by our enhanced commercial team, along with support from a broad base of glaucoma specialists and comprehensive ophthalmologists advocating for the use of our G6 platform to treat the spectrum of the disease. This progress is encouraging and creating additional opportunities to drive installed base growth and increased utilization.”

Third Quarter 2018 Financial Results

Revenue for the three months ended September 29, 2018 of $11.3 million increased from $10.9 million during the same period of the prior year. The increase in revenue was driven by growth from G6 product revenues and relatively flat retina product revenues.

Gross profit for the third quarter of 2018 was $4.6 million, or 40.4% gross margin, compared to $4.4 million, or 40.2% gross margin, in the same period of the prior year. Gross margin was primarily impacted by a favorable shift in product mix and a decrease in manufacturing variances and manufacturing overhead spending, partially offset by an unfavorable geographic mix.

Operating expenses for the third quarter of 2018 were $7.6 million compared to $7.4 million in the same period of the prior year. This increase is attributable to investments to support the Company’s commercial infrastructure, including increased sales and marketing expenses.

Loss from operations for the third quarter of 2018 was $3.1 million, compared to loss from operations of $3.1 million for the same period of the prior year.

Cash and cash equivalents were $23.7 million as of September 29, 2018.

Exhibit 99.1

Guidance for Full Year 2018

IRIDEX increased its guidance range for G6 systems and total revenue. The Company now expects G6 system shipments of 430 to 450 and total revenue of $41 million to $42 million. This compares to previous 2018 guidance of G6 system shipments of 370 to 420 and total revenue of $38 million to $41 million. The Company also raised the lower end of its 2018 G6 probe shipments guidance to a range of 44,000 to 46,000. This compares to previous guidance of 42,000 to 46,000 G6 probes shipments.

Webcast and Conference Call Information

IRIDEX’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 2098999. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com. A telephone replay will also be available beginning Thursday, November 1, 2018 through Friday, November 3, 2018, by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 2098999.

About IRIDEX

IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future demand and order levels for the Company's products, future operating expenses, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, the Company’s guidance for fiscal 2018 and future financial results, and the Company's strategic and operational plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Investor Relations Contact

Lynn Pieper Lewis or Leigh Salvo

(415) 937-5404

investors@iridex.com

Exhibit 99.1

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

	Three Months Ended						Nine Months Ended
	September 29,			September 30,			September 29,				September 30,
	2018			2017			2018				2017

Total revenues	$	11,320		$	10,865		$		31,133		$		31,350
Cost of revenues		6,744			6,492				18,367				18,017
Gross profit		4,576			4,373				12,766				13,333

Operating expenses:
Research and development		1,149			1,320				3,154				4,028
Sales and marketing		4,144			3,769				12,362				10,346
General and administrative		2,343			2,530				7,209				6,804
Gain on sale of intellectual property		-			(175	)		-				(175		)
Total operating expenses		7,636			7,444				22,725				21,003

Loss from operations		(3,060	)		(3,071	)			(9,959	)			(7,670	)
Other (expense) income, net		(8	)		(16	)			16				(19	)
Loss from operations before provision for income taxes		(3,068	)		(3,087	)			(9,943	)			(7,689	)
Provision for income taxes		6			9				14				23
Net loss	$	(3,074	)	$	(3,096	)	$		(9,957	)	$		(7,712	)

Net loss per share:
Basic	$	(0.26	)	$	(0.27	)	$		(0.85	)	$		(0.67	)
Diluted	$	(0.26	)	$	(0.27	)	$		(0.85	)	$		(0.67	)

Weighted average shares used in computing net loss per share
Basic		11,925			11,569				11,732				11,544
Diluted		11,925			11,569				11,732				11,544

Exhibit 99.1

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands and unaudited)

	September 29,			December 30,
	2018			2017
Assets
Current assets:
Cash and cash equivalents	$	23,725		$	21,707
Accounts receivable, net		8,430			7,863
Inventories		8,725			9,381
Prepaid expenses and other current assets		492			500
Total current assets		41,372			39,451
Property and equipment, net		1,312			1,403
Intangible assets, net		104			116
Goodwill		533			533
Other long-term assets		216			143
Total assets	$	43,537		$	41,646


Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	2,552		$	1,724
Accrued compensation		2,284			2,459
Accrued expenses		2,643			2,153
Accrued warranty		694			1,536
Deferred revenue		2,217			2,520
Total current liabilities		10,390			10,392

Long-term liabilities:
Accrued warranty		138			199
Other long-term liabilities		400			533
Total liabilities		10,928			11,124

Stockholders' equity:
Common stock		145			126
Additional paid-in capital		71,283			59,385
Accumulated other comprehensive income		127			-
Accumulated deficit		(38,946	)		(28,989	)
Total stockholders' equity		32,609			30,522

Total liabilities and stockholders' equity	$	43,537		$	41,646

Exhibit 99.1